Anthos Therapeutics reposted this
Anthos Therapeutics provided an update on the study into a new anticoagulant designed to reduce bleeding among people undergoing treatment for atrial fibrillation who are at a moderate-to-high risk of stroke. Last fall, the AZALEA-TIMI 71 study was stopped early because the data showed a significant reduction in bleeding in people taking the new medication, abelacimab, compared to rivaroxaban, an anticoagulant that became available more than a decade ago. Patients who participated in the study were given the option to switch to abelacimab going forward, and 84% opted to do so. Abelacimab is a new and highly selective antibody made from human proteins that locks factor XI — a protein that plays an important role in blood clotting — in an inactive state. Abelacimab has not yet been approved by the FDA, but studies are showing promising results. Read more: https://lnkd.in/evMPKdAb #stoptheclot #bloodclots #abelacimab #afib #atrialfibrillation #bloodclots #bloodclotprevention #anthostherapeutics #pharmaceuticalresearch
